Toronto, ON and New Haven, CT – Dalton Medicinal Chemistry and BioRelix say they have jointly formed a research collaboration to discover new therapeutics.
BioRelix is building a portfolio of anti-infective products based on novel patented RNA targets. Dalton will use the therapeutic agents to design and synthesize several novel classes of compounds against selected targets. BioRelix will advance these compounds using their biological assays and thorough knowledge of drug discovery and development.
“We are delighted to have this opportunity to work with BioRelix in the discovery of much needed new anti-infective agents,” says Judd Berman, co-founder of Dalton Medicinal Chemistry. “The team at BioRelix has clearly established an exceptionally innovative approach to anti-infectives.”
Dalton is a contract pharmaceutical manufacturer that supplies chemistry and analytical services to the biotechnology and pharmaceutical industries in the areas of chemistry, medicinal chemistry and fine chemical manufacture. BioRelix is a drug discovery and development company focused on identifying new anti-infective drug treatments.